fashion -WSS

fashion

author：explore 2025-09-30 01:02:42 - browse：9516

A phone screen displays the webpage of Medicare.gov — coverage from STAT — Adobe

Over the past few weeks, Medicare Advantage insurers demanded that the Biden administration give them higher payment rates for next year. The government’s data on how much people were using health care didn’t match their own data, insurers and lobbyists griped — and therefore they wouldn’t be paid enough to cover those costs.

But the federal government was not persuaded by the industry’s data or lobbying push. The Biden administration and its Medicare agency decided to stick with their proposals from January on Monday, dealing a blow to an insurance industry that has come to rely on Medicare Advantage for a steady stream of profits.

The result: In 2025, right after a new president is elected, Medicare Advantage insurers will have to absorb a slight decrease of 0.2% to the baseline payment rates that insurers receive from the government for enrolling older adults and people with disabilities. The stock prices of the largest Medicare Advantage insurers — UnitedHealth, Humana, CVS Health, and Elevance Health — all fell by at least 4% in after-hours trading.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Medicare eyes cuts to doctors, raises to outpatient clinics in 2024

hotspot

WSS

Grail faces three suits alleging harassment, retaliation

Indian pharmaceutical industry in denial over drug

Special counsel informs Trump he is target in probe of efforts to overturn 2020 election

Grail faces three suits alleging harassment, retaliation

Blood tests recalled over risk of missed heart attack diagnosis

Jury awards Florida girl burned by McDonald's Chicken McNugget $800,000 in damages

focus

fashion

entertainment

As demand for Covid shots wanes, Moderna seeks its next success

American woman kidnapped in Mexico freed after 8 months in captivity: FBI

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Judge rejects Trump's request to move Stormy Daniels hush

DIEP, the 'gold standard' of breast reconstruction, is under threat

Care demand spikes challenge UnitedHealth’s provider arm

Duchenne breakthrough therapy leaves behind pioneering families

Study identifies new proteins linked to dementia risk 25 years later

Hepatitis C has a cure — but many Americans still lack access to it

The new HIV moral panic

Wikipedia

Tocagen's brain cancer gene therapy trial continues. Investors worry

Winning ticket for $1 billion Powerball jackpot sold in California

RFK Jr. accused of antisemitic claims about COVID but insists he was misunderstood

Congress likely to miss an opportunity to fix drug shortages issue

Judge rejects Trump's request to move Stormy Daniels hush

Involuntary treatment for addiction doesn't work

explore

hotspot

knowledge

focus